Page 4 - Pascal Deschatelets News Today

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 16,770,000 shares, an increase of 23.2% from the September 15th total of 13,610,000 shares. Based on an average daily volume of 5,100,000 shares, […]

On October 9, 2023, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), sold 12,000 shares of the company.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $37.62, but opened at $36.54. Apellis Pharmaceuticals shares last traded at $37.41, with a volume of 1,363,581 shares traded. Wall Street Analysts Forecast Growth Several analysts have recently issued reports on […]

EcoR1 Capital LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 5.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,451,647 shares of the company’s stock after purchasing an additional 268,216 shares during the quarter. Apellis […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $42.87, for a total value of $514,440.00. Following the transaction, the insider now owns 1,059,813 shares in the company, valued […]

Apellis Pharmaceuticals (NASDAQ: APLS) has recently received a number of price target changes and ratings updates: 8/30/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock. 8/29/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Citigroup […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $60.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 42.15% from the […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target boosted by investment analysts at Stifel Nicolaus from $60.00 to $65.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 60.06% from the company’s […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective raised by research analysts at Citigroup from $45.00 to $54.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 32.97% from the company’s current price. […]

Nicholas Investment Partners LP raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 35.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 336,951 shares of the company’s stock after purchasing an additional 88,668 shares during the period. Apellis Pharmaceuticals […]